Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral: Vanier Canada Graduate Scholarships

University of Ottawa

$150,000.00

Oncolytic immunotherapy-driven synthetic lethality for Breast Cancer

FY 2021-22

Summary
Breast Cancer is the second most common cancer in Canada and the most common cancer among Canadian females. Poly(ADP-ribose) polymerase inhibitors have been approved by Food and Drug Administration for cancers with faults in one of the BRCA genes. But despite the patients' initial promising response to these inhibitors, cancer develops resistance due to the tumor's genomic instability and heterogeneity. So, a solution to restore tumor cells' susceptibility to these molecules is needed. microRNAs are used to down-regulate cancer-specific targets for this purpose. But safe and efficient delivery of microRNAs to the tumor sites is yet to be developed. Oncolytic viruses are exciting therapeutic agents for cancer treatment as they specifically infect and kill cancer cells and induce anti-tumor immunity. We have previously shown the ability of oncolytic rhabdoviruses to induce tumor cell expression of multiple therapeutic payloads, including microRNAs. They are packaged into exosomes, their natural carriers, and are released from the infected cell to surrounding uninfected cells. In this project, I propose to generate a multi-modal oncolytic virus-based therapy that specifically replicates in and destroys tumor cells and sensitizes uninfected cells to the mentioned inhibitors, acting in a synthetic lethal manner. It will provide the proof of principle that oncolytic viruses have multiple therapeutic mechanisms of action: the direct induction of oncolysis, the induction of host anti-tumor immunity, the delivery of therapeutic microRNAs that can be disseminated within the tumor microenvironment by exosomal delivery, and the sensitization of target cells to mentioned inhibitors irrespective to their genomic signature. The result of this study will present a one-of-a-kind novel combinational therapy modality for breast cancer. In the future, I will focus on expanding the repertoire of DNA damage response genes targeted by our oncolytic rhabdoviruses to complete this toolbox.
Program
Doctoral: Vanier Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
457642
Name
Jamalkhah Choshali Monire
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
Oncolytic immunotherapy-driven synthetic lethality for Breast Cancer
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Brca Mutation-Bearing Breast Cancer; Immunotherapy Of Cancer; In Situ Production Of Mirna-Loaded Exosoms; Oncolytic Virotherapy; Restoration Of Drug Resistance; Small Inhibitory Rna Technique To Down-Regulate Genes; Synthetic Lethality
Abstract
Breast Cancer is the second most common cancer in Canada and the most common cancer among Canadian females. Poly(ADP-ribose) polymerase inhibitors have been approved by Food and Drug Administration for cancers with faults in one of the BRCA genes. But despite the patients' initial promising response to these inhibitors, cancer develops resistance due to the tumor's genomic instability and heterogeneity. So, a solution to restore tumor cells' susceptibility to these molecules is needed. microRNAs are used to down-regulate cancer-specific targets for this purpose. But safe and efficient delivery of microRNAs to the tumor sites is yet to be developed. Oncolytic viruses are exciting therapeutic agents for cancer treatment as they specifically infect and kill cancer cells and induce anti-tumor immunity. We have previously shown the ability of oncolytic rhabdoviruses to induce tumor cell expression of multiple therapeutic payloads, including microRNAs. They are packaged into exosomes, their natural carriers, and are released from the infected cell to surrounding uninfected cells. In this project, I propose to generate a multi-modal oncolytic virus-based therapy that specifically replicates in and destroys tumor cells and sensitizes uninfected cells to the mentioned inhibitors, acting in a synthetic lethal manner. It will provide the proof of principle that oncolytic viruses have multiple therapeutic mechanisms of action: the direct induction of oncolysis, the induction of host anti-tumor immunity, the delivery of therapeutic microRNAs that can be disseminated within the tumor microenvironment by exosomal delivery, and the sensitization of target cells to mentioned inhibitors irrespective to their genomic signature. The result of this study will present a one-of-a-kind novel combinational therapy modality for breast cancer. In the future, I will focus on expanding the repertoire of DNA damage response genes targeted by our oncolytic rhabdoviruses to complete this toolbox.
Competitiondate
202111
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Jamalkhah Choshali, Monire
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~
University of Ottawa - $150,000 Grant (2021-22) | Canada Spends